ArticleBMC pulmonary medicine2026
Progressive pulmonary fibrosis criteria predict mortality in treated idiopathic pulmonary fibrosis: a prospective cohort study.
Article in BMC pulmonary medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundThe 2022 ATS/ERS/JRS/ALAT criteria for progressive pulmonary fibrosis (PPF) were developed for fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (IPF). Whether this multidimensional framework has prognostic value in patients with treated IPF remains uncertain. We evaluated the prevalence of PPF-defined progression and its association with mortality in patients with IPF receiving antifibrotic therapy.
methodsThis prospective cohort study included patients with multidisciplinary discussion-confirmed IPF enrolled in the Registry of Interstitial Lung Disease (REGILD) between 2018 and 2022. Disease progression was assessed one year after initiation of antifibrotic therapy using the 2022 PPF criteria. The primary outcome was 3-year all-cause mortality. Cox regression and nested Cox model analyses were performed to identify prognostic factors and evaluate incremental prognostic value beyond the GAP score.
resultsNinety patients were included, of whom 50 (55.6%) fulfilled PPF criteria after one year of antifibrotic therapy. During a median follow-up of 3.6 years, 28 patients (31.1%) died. Three-year mortality was significantly higher in patients with PPF-defined progression than in those with stable disease (46.0% vs. 12.5%, p = 0.001). In multivariable analysis, lower baseline body mass index (BMI) (HR 0.87, 95% CI 0.78-0.96, p = 0.006) and PPF-defined progression (HR 3.39, 95% CI 1.23-9.34, p = 0.018) were independently associated with mortality. Addition of PPF-defined progression to a model containing the GAP score significantly improved model fit (Δχ² = 5.610, p = 0.018).
conclusionsPPF-defined progression and lower baseline BMI were independently associated with mortality in patients with IPF receiving antifibrotic therapy. PPF-defined progression provided incremental prognostic information beyond the GAP score, suggesting that assessment of longitudinal disease trajectory may complement conventional baseline risk stratification in treated IPF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.